应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BRVE Braveheart Bio
交易中 08-07 15:51:18 EDT
30.03
+0.23
+0.77%
最高
31.20
最低
28.47
成交量
33.06万
今开
29.70
昨收
29.80
日振幅
9.18%
总市值
21.22亿
流通市值
5.63亿
总股本
7,065万
成交额
989.25万
换手率
1.76%
流通股本
1,875万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读 | IPO首日表现强劲,Braveheart Bio盘中大涨67.78%
异动解读 · 08-07 00:52
异动解读 | IPO首日表现强劲,Braveheart Bio盘中大涨67.78%
美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%
智通财经 · 08-07 00:00
美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%
美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%
智通财经 · 08-07 00:00
美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%
生物科技IPO热潮持续!心血管药企Braveheart(BRVE.US)募资扩大至3.825亿美元,发行价突破指引上限
智通财经 · 08-06 16:28
生物科技IPO热潮持续!心血管药企Braveheart(BRVE.US)募资扩大至3.825亿美元,发行价突破指引上限
Braveheart Bio(BRVE.US)IPO定价15-17美元/股,拟募资3亿美元推进心血管药物全球三期临床
智通财经 · 07-31
Braveheart Bio(BRVE.US)IPO定价15-17美元/股,拟募资3亿美元推进心血管药物全球三期临床
暂无数据
公司概况
公司名称:
Braveheart Bio
所属市场:
NASDAQ
上市日期:
--
主营业务:
Braveheart Bio, Inc.于2024年5月13日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,专注于为肥厚型心肌病和其他严重心血管疾病患者开发疗法。其主导候选产品BHB-1893是一种下一代口服小分子心肌肌球蛋白抑制剂,由江苏恒瑞医药有限公司获得全球授权,不包括大中华区,并已在恒瑞主要在中国和澳大利亚进行的临床试验中进行评估。
发行价格:
--
{"stockData":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":30.03,"timestamp":1786132240256,"preClose":29.8,"halted":0,"volume":330625,"delay":0,"changeRate":0.007718120805369141,"floatShares":18750000,"shares":70652838,"eps":-1.136,"marketStatus":"交易中","change":0.23,"latestTime":"08-07 15:51:18 EDT","open":29.7,"high":31.2,"low":28.465,"amount":9892508.624375,"amplitude":0.091779,"askPrice":30.16,"askSize":200,"bidPrice":29.65,"bidSize":201,"shortable":3,"etf":0,"ttmEps":-1.136,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786132800000},"marketStatusCode":2,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":29.8,"preHourTrading":{"tag":"盘前","latestPrice":29.65,"preClose":29.8,"latestTime":"09:25 EDT","volume":768,"amount":23056.038912,"timestamp":1786109147980,"change":-0.15,"changeRate":-0.005034,"amplitude":0.045638},"postHourTrading":{"tag":"盘后","latestPrice":30.164,"preClose":29.8,"latestTime":"19:34 EDT","volume":3659,"amount":108873.4268,"timestamp":1786059244552,"change":0.364,"changeRate":0.012215,"amplitude":0.025168},"volumeRatio":0.10253},"requestUrl":"/m/hq/s/BRVE/tweets","defaultTab":"tweets","newsList":[{"id":"1138238457","title":"异动解读 | IPO首日表现强劲,Braveheart Bio盘中大涨67.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138238457","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138238457?lang=zh_cn&edition=full","pubTime":"2026-08-07 00:52","pubTimestamp":1786035174,"startTime":"0","endTime":"0","summary":"心血管药物开发商Braveheart Bio今日在纳斯达克首日上市交易,盘中股价大涨67.78%,引发市场广泛关注。Braveheart Bio总部位于加州旧金山,是一家处于临床后期的生物制药公司,专注于开发肥厚型心肌病及其他严重心血管疾病的创新疗法。在2026年生物科技IPO热潮的背景下,Braveheart Bio的成功上市进一步彰显了市场对创新药企的强劲信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656478","title":"美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656478","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657656478?lang=zh_cn&edition=full","pubTime":"2026-08-07 00:00","pubTimestamp":1786032000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周四,心血管药企Braveheart Bio(BRVE.US)登陆美股市场,截至发稿,该股涨超75%,报31.405美元。IPO价格为18美元。Braveheart Bio成立于2024年,是一家处于临床后期的生物制药公司,专注于开发肥厚型心肌病(HCM)及其他严重心血管疾病的创新疗法。公司的核心候选药物BHB-1893(亦称HRS-1893)是一种口服小分子心肌肌球蛋白抑制剂,通过特异性抑制心肌肌球蛋白ATP酶活性,使心肌收缩性能正常化,减少左心室肥厚并改善舒张期顺应性。该药物于2025年9月从中国江苏恒瑞医药获得全球(除大中华区外)独家许可授权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656475","title":"美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657656475?lang=zh_cn&edition=full","pubTime":"2026-08-07 00:00","pubTimestamp":1786032000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657070685","title":"生物科技IPO热潮持续!心血管药企Braveheart(BRVE.US)募资扩大至3.825亿美元,发行价突破指引上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2657070685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657070685?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:28","pubTimestamp":1786004901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","AGNG","GDOC","REDS","FRHC","BK4585","IBBJ","XBI","LNGR","BK4581","KCE","IPOS","BRVE","MEDX","SYNB","IEIH","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655330649","title":"Braveheart Bio(BRVE.US)IPO定价15-17美元/股,拟募资3亿美元推进心血管药物全球三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2655330649","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655330649?lang=zh_cn&edition=full","pubTime":"2026-07-31 14:34","pubTimestamp":1785479661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UUP","IPOS","BRVE","UDN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.braveheart.bio","stockEarnings":[{"period":"1week","weight":0.6556},{"period":"ytd","weight":0.6556}],"compareEarnings":[{"period":"1week","weight":0.0362},{"period":"1month","weight":0.0279},{"period":"3month","weight":0.0419},{"period":"6month","weight":0.1129},{"period":"1year","weight":0.2146},{"period":"ytd","weight":0.1271}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Braveheart Bio, Inc.于2024年5月13日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,专注于为肥厚型心肌病和其他严重心血管疾病患者开发疗法。其主导候选产品BHB-1893是一种下一代口服小分子心肌肌球蛋白抑制剂,由江苏恒瑞医药有限公司获得全球授权,不包括大中华区,并已在恒瑞主要在中国和澳大利亚进行的临床试验中进行评估。","exchange":"NASDAQ","name":"Braveheart Bio","nameEN":"Braveheart Bio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Braveheart Bio(BRVE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Braveheart Bio(BRVE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Braveheart Bio,BRVE,Braveheart Bio股票,Braveheart Bio股票老虎,Braveheart Bio股票老虎国际,Braveheart Bio行情,Braveheart Bio股票行情,Braveheart Bio股价,Braveheart Bio股市,Braveheart Bio股票价格,Braveheart Bio股票交易,Braveheart Bio股票购买,Braveheart Bio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Braveheart Bio(BRVE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Braveheart Bio(BRVE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}